02:53 PM EDT, 06/14/2024 (MT Newswires) -- Novavax ( NVAX ) said Friday it has filed an Emergency Use Authorization amendment to the US Food and Drug Administration for its updated JN.1 COVID-19 vaccine for individuals aged 12 and older.

Novavax ( NVAX ) said its updated vaccine is active against current circulating strains, including KP.2 and KP.3, and would be the only protein-based option available in the US.

The company said it plans to have the vaccine ready for US distribution by mid-August post-authorization and following recommendation by the US Centers for Disease Control and Prevention.

Price: 14.31, Change: -0.74, Percent Change: -4.90